355 related articles for article (PubMed ID: 19524180)
21. Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy.
Delgrange E; Duprez T; Maiter D
Clin Endocrinol (Oxf); 2006 Apr; 64(4):456-62. PubMed ID: 16584520
[TBL] [Abstract][Full Text] [Related]
22. Non-surgical management of cystic prolactinomas.
Bahuleyan B; Menon G; Nair S; Rao BR; Easwer HV; Krishna K
J Clin Neurosci; 2009 Nov; 16(11):1421-4. PubMed ID: 19699096
[TBL] [Abstract][Full Text] [Related]
23. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.
Colao A; Vitale G; Cappabianca P; Briganti F; Ciccarelli A; De Rosa M; Zarrilli S; Lombardi G
J Clin Endocrinol Metab; 2004 Apr; 89(4):1704-11. PubMed ID: 15070934
[TBL] [Abstract][Full Text] [Related]
24. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
Colao A; Di Sarno A; Landi ML; Scavuzzo F; Cappabianca P; Pivonello R; Volpe R; Di Salle F; Cirillo S; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 2000 Jun; 85(6):2247-52. PubMed ID: 10852458
[TBL] [Abstract][Full Text] [Related]
25. Long-term outcome of macroprolactinomas.
Képénékian L; Cebula H; Castinetti F; Graillon T; Brue T; Goichot B
Ann Endocrinol (Paris); 2016 Dec; 77(6):641-648. PubMed ID: 27641080
[TBL] [Abstract][Full Text] [Related]
26. Dopamine agonists and valvular heart disease.
Cheung D; Heaney A
Curr Opin Endocrinol Diabetes Obes; 2009 Aug; 16(4):316-20. PubMed ID: 19506475
[TBL] [Abstract][Full Text] [Related]
27. Chiasmal herniation as a complication of bromocriptine therapy.
Taxel P; Waitzman DM; Harrington JF; Fagan RH; Rothfield NF; Chen HH; Malchoff CD
J Neuroophthalmol; 1996 Dec; 16(4):252-7. PubMed ID: 8956160
[TBL] [Abstract][Full Text] [Related]
28. Giant prolactinomas: clinical management and long-term follow up.
Shrivastava RK; Arginteanu MS; King WA; Post KD
J Neurosurg; 2002 Aug; 97(2):299-306. PubMed ID: 12186457
[TBL] [Abstract][Full Text] [Related]
29. Factors determining the remission of microprolactinomas after dopamine agonist withdrawal.
Huda MS; Athauda NB; Teh MM; Carroll PV; Powrie JK
Clin Endocrinol (Oxf); 2010 Apr; 72(4):507-11. PubMed ID: 19549247
[TBL] [Abstract][Full Text] [Related]
30. Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth.
Greenman Y; Tordjman K; Osher E; Veshchev I; Shenkerman G; Reider-Groswasser II; Segev Y; Ouaknine G; Stern N
Clin Endocrinol (Oxf); 2005 Jul; 63(1):39-44. PubMed ID: 15963059
[TBL] [Abstract][Full Text] [Related]
31. Hyperprolactinaemia.
Prabhakar VK; Davis JR
Best Pract Res Clin Obstet Gynaecol; 2008 Apr; 22(2):341-53. PubMed ID: 17889620
[TBL] [Abstract][Full Text] [Related]
32. The use of surgery for the treatment of prolactinomas.
van't Verlaat JW
Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():34-7. PubMed ID: 8103958
[TBL] [Abstract][Full Text] [Related]
33. Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma.
Raverot G; Jacob M; Jouanneau E; Delemer B; Vighetto A; Pugeat M; Borson-Chazot F
Clin Endocrinol (Oxf); 2009 Apr; 70(4):588-92. PubMed ID: 18673461
[TBL] [Abstract][Full Text] [Related]
34. Management of pituitary apoplexy: clinical experience with 40 patients.
Lubina A; Olchovsky D; Berezin M; Ram Z; Hadani M; Shimon I
Acta Neurochir (Wien); 2005 Feb; 147(2):151-7; discussion 157. PubMed ID: 15570437
[TBL] [Abstract][Full Text] [Related]
35. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
[TBL] [Abstract][Full Text] [Related]
36. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
37. MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment.
Eroukhmanoff J; Tejedor I; Potorac I; Cuny T; Bonneville JF; Dufour H; Weryha G; Beckers A; Touraine P; Brue T; Castinetti F
Eur J Endocrinol; 2017 Mar; 176(3):323-328. PubMed ID: 28073906
[TBL] [Abstract][Full Text] [Related]
38. Complete remission of macroprolactinoma after long-term medical therapy with dopamine agonists.
Iglesias P; Díez JJ
QJM; 2011 Aug; 104(8):721-2. PubMed ID: 20663808
[No Abstract] [Full Text] [Related]
39. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
Hamilton DK; Vance ML; Boulos PT; Laws ER
Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
[TBL] [Abstract][Full Text] [Related]
40. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas.
Biswas M; Smith J; Jadon D; McEwan P; Rees DA; Evans LM; Scanlon MF; Davies JS
Clin Endocrinol (Oxf); 2005 Jul; 63(1):26-31. PubMed ID: 15963057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]